The spectre of ghostwriting: eroding public trust in physicians, clinical trial integrity and biomedical authorship

International Journal of Clinical Practice

Volumn 70, Issue 7, 2016, Pages 630-633

  DeTora, L M ^a  

^a HOFSTRA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; ETHICS; EVIDENCE BASED MEDICINE; GHOSTWRITING; GOVERNMENT; HUMAN; LANGUAGE; MEDICAL LITERATURE; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; PUBLISHING; SCIENTIST; UNITED STATES; WRITING;

EID: 84977581002     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12839     Document Type: Article

References (23)

1. Loder E, Godlee F, Barbour V, Winker M; PLoS Medicine Editors. Restoring the integrity of the clinical trial evidence base. BMJ 2013; 346: f3601. http://www.bmj.com/content/346/bmj.f3601.long (accessed 25 March 2016).
2. Flaherty DK. Ghost- and guest-authored pharmaceutical industry-sponsored studies: abuse of academic integrity, the peer review system, and public trust. Ann Pharmacother 2013; 47: 1081–3. http://aop.sagepub.com/content/47/7-8/1081.long (accessed 25 March 2016).
3. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. PLoS Med 2007; 4(1): e19. http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0040019 (accessed 25 March 2016).
4. Stretton S. Systematic review on the primary and secondary reporting of the prevalence of ghostwriting in the medical literature. BMJ Open 2014; 4(7): e004777. doi: 10.1136/bmjopen-2013-004777.
5. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 2007; 4(9): e286. doi:10.1371/journal.pmed.0040286.
6. Flanagin A, Carey LA, Fontanarosa PB, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 1998; 280(3): 222–4. http://jama.jamanetwork.com/article.aspx?articleid=187772 (accessed 25 March 2016).
7. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008; 299(15): 1800–12. doi:10.1001/jama.299.15.1800.
8. Wislar JS, Flanagin A, Fontanarosa PB, Deangelis CD. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ 2011; 343(d6128): 2016. doi:10.1136/bmj.d6128.
9. International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals, 2014. http://www.icmje.org/recommendations/ (accessed 13 April 2016).
10. World Association of Medical Editors Authorship policy statement, 2007. http://www.wame.org/policy-statements#Authorship (accessed 13 April 2016).
11. Gorry P. Medical literature imprinting by pharma ghost writing: a scientometric evaluation. Proceedings of the ISSI 2015 Meeting. Istanbul, 2015. http://www.issi2015.org/files/downloads/all-papers/0650.pdf (accessed 25 March 2016).
12. Grassley C., ed. Ghostwriting in medical literature. Minority Staff Report, 111th Congress, United States Senate Committee on Finance (June 24, 2010). http://www.grassley.senate.gov/sites/default/files/about/upload/Senator-Grassley-Report.pdf (accessed 4 May 2015).
13. Singer N. Report urges more curbs on medical ghostwriting. New York Times. 24 June, 2010. http://www.nytimes.com/2010/06/25/health/25ghost.html?_r=0 (accessed 25 March 2016).
14. Goldacre B. Medical ghostwriters who build a brand. The Guardian. 18 September, 2010. http://www.theguardian.com/commentisfree/2010/sep/18/bad-science-medical-ghostwriters (accessed 13 April 2016).
15. Ross E. How drug companies PR tactics skew the presentation of medical research. The Guardian, 20 May 2011. https://www.theguardian.com/science/2011/may/20/drug-companies-ghost-writing-journalism (accessed 13 April 2016).
16. Hinkes-Jones L. Stop subsidizing big pharma. New York Times. 5 January, 2015. http://www.nytimes.com/2015/01/06/opinion/stop-subsidizing-big-pharma.html (accessed 25 March 2016).
17. Levine A. Feds pay for drug fraud: 92 percent of foster care, poor kids prescribed antipsychotics get them for unaccepted uses. Huffington Post. Updated May 30, 2015. http://www.huffingtonpost.com/art-levine/feds-pay-for-drug-fraud-9_b_6966454.html (accessed 25 March 2016).
18. Brill S. America's most admired lawbreaker. Huffington Post, 2015. http://highline.huffingtonpost.com/miracleindustry/americas-most-admired-lawbreaker/ (accessed 25 March 2016).
19. United States Office of the Inspector General. Second-generation antipsychotic drug use among Medicaid-enrolled children: quality-of-care concerns, 2015. http://oig.hhs.gov/oei/reports/oei-07-12-00320.pdf (accessed 25 March 2016).
20. Bridges D. Closed meeting presentation/Personal Communication. G-Max Workshop. Copenhagen: Novo-Nordisk, Inc., October 2013.
21. Citrome L, Karagianis J, Maguire GA, Nierenberg AA. Pharmaism: a tale of two perspectives. Int J Clin Pract 2014; 68(6): 659–61. doi: 10.1111/ijcp.12460.
22. Kingdom W. Pharmaism. Med Writing 2013; 22(4): 262–3.
23. Davidoff F, DeAngelis CD, Drazen JM, et al. (2001) Sponsorship, authorship, and accountability. N Engl J Med 345: 825–6. http://www.nejm.org/doi/full/10.1056/NEJMed010093 (accessed 25 March 2016).